Sanofi on Thursday became the last major insulin maker to cut the price of the life-saving drug. Here’s why it’s been so expensive and what’s next.
Author: Ken Alltucker, USA TODAY
Eli Lilly to cut insulin prices up to 70% amid federal pressure to lower costs
Drugmaker Eli Lilly says it will cut its insulin prices up to 70% and cap out-of-pocket costs for privately-insured consumers at $35 per month.
US nursing homes aren’t safe amid climate crisis, report finds. And it’s getting worse.
A Senate committee report highlights the risks seniors and disabled residents face during extreme heat or cold, floods, tornadoes or wildfires.
3 teen girls killed in apparent murder-suicide in Texas; 12-year-old escapes after assault
Three teenage girls, including one who was pregnant, were fatally shot Saturday night by man who then killed himself in an apparent murder-suicide.
One dead, 10 injured in Memphis shooting; 3 people of interest sought
One person died and 10 were injured early Sunday after gunfire erupted at the Live Lounge nightclub in Memphis, police said.
First it was blood pressure medication. Now FDA eyes more drugs for cancer-causing chemical.
Here’s what the FDA is doing to protect consumers after drugs such as quinapril, Zantac and Metformin were recalled over chemicals linked to cancer.
Medicare targets drug companies that raise prices above rate of inflation
Medicare’s rebate authority comes from the Inflation Reduction Act, which also empowers the federal government to negotiate drug prices.
Here’s why Medicaid coverage and free COVID tests, treatments will soon change
About 15 million may lose health insurance in May when the COVID emergency ends. Meanwhile, free vaccines and treatments will end by summer.
Arthritis drug Humira’s two-decade reign ends as Amgen launches competing biosimilar
The price of Amgen’s rheumatoid arthritis drug called Amjevita is up to 55% less than the widely-prescribed Humira.
Biden seeks to bolster the Affordable Care Act’s no-cost contraception rule
The proposed rule would remove an employer’s ability to object to contraceptive coverage on moral grounds while still allowing religious objections.